Vir Biotechnology Files Q3 2024 10-Q
Ticker: VIR · Form: 10-Q · Filed: 2024-11-04T00:00:00.000Z
Sentiment: neutral
Topics: 10-Q, biotechnology, financials
TL;DR
Vir Bio's Q3 10-Q is in. Check financials for latest performance.
AI Summary
Vir Biotechnology, Inc. filed its 10-Q for the period ending September 30, 2024. The company reported its financial results and provided updates on its business operations. Specific financial figures and operational details are available within the full filing.
Why It Matters
This filing provides investors with the latest financial performance and operational status of Vir Biotechnology, crucial for understanding the company's trajectory and investment potential.
Risk Assessment
Risk Level: medium — As a biotechnology company, Vir faces inherent risks related to drug development, regulatory approvals, and market competition.
Key Players & Entities
- Vir Biotechnology, Inc. (company) — Filer of the 10-Q
- 2024-09-30 (date) — End of the reporting period
- 2024-11-04 (date) — Filing date
FAQ
What is the reporting period for this 10-Q filing?
The reporting period for this 10-Q filing is the quarter ended September 30, 2024.
When was this 10-Q filed with the SEC?
This 10-Q was filed on November 4, 2024.
What is the company's Standard Industrial Classification (SIC) code?
The SIC code for Vir Biotechnology, Inc. is 2836, which corresponds to Biological Products (No Diagnostic Substances).
Where is Vir Biotechnology, Inc. headquartered?
Vir Biotechnology, Inc. is headquartered in San Francisco, California.
What is the fiscal year end for Vir Biotechnology, Inc.?
The fiscal year end for Vir Biotechnology, Inc. is December 31.
From the Filing
0001628280-24-044995.txt : 20241104 0001628280-24-044995.hdr.sgml : 20241104 20241104160950 ACCESSION NUMBER: 0001628280-24-044995 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 74 CONFORMED PERIOD OF REPORT: 20240930 FILED AS OF DATE: 20241104 DATE AS OF CHANGE: 20241104 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Vir Biotechnology, Inc. CENTRAL INDEX KEY: 0001706431 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 812730369 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-39083 FILM NUMBER: 241423582 BUSINESS ADDRESS: STREET 1: 1800 OWENS STREET STREET 2: SUITE 900 CITY: SAN FRANCISCO STATE: CA ZIP: 94158 BUSINESS PHONE: 415-906-4324 MAIL ADDRESS: STREET 1: 1800 OWENS STREET STREET 2: SUITE 900 CITY: SAN FRANCISCO STATE: CA ZIP: 94158 10-Q 1 vir-20240930.htm 10-Q vir-20240930 12/31 false 0001706431 2024 Q3 P3Y http://fasb.org/us-gaap/2024#AccruedLiabilitiesAndOtherLiabilities http://fasb.org/us-gaap/2024#AccruedLiabilitiesAndOtherLiabilities 167 xbrli:shares iso4217:USD iso4217:USD xbrli:shares xbrli:pure vir:option vir:engager vir:program vir:pathogen vir:position 0001706431 2024-01-01 2024-09-30 0001706431 2024-10-25 0001706431 2024-09-30 0001706431 2023-12-31 0001706431 vir:CollaborationRevenueMember 2024-07-01 2024-09-30 0001706431 vir:CollaborationRevenueMember 2023-07-01 2023-09-30 0001706431 vir:CollaborationRevenueMember 2024-01-01 2024-09-30 0001706431 vir:CollaborationRevenueMember 2023-01-01 2023-09-30 0001706431 vir:ContractRevenueMember 2024-07-01 2024-09-30 0001706431 vir:ContractRevenueMember 2023-07-01 2023-09-30 0001706431 vir:ContractRevenueMember 2024-01-01 2024-09-30 0001706431 vir:ContractRevenueMember 2023-01-01 2023-09-30 0001706431 us-gaap:GrantMember 2024-07-01 2024-09-30 0001706431 us-gaap:GrantMember 2023-07-01 2023-09-30 0001706431 us-gaap:GrantMember 2024-01-01 2024-09-30 0001706431 us-gaap:GrantMember 2023-01-01 2023-09-30 0001706431 2024-07-01 2024-09-30 0001706431 2023-07-01 2023-09-30 0001706431 2023-01-01 2023-09-30 0001706431 us-gaap:CommonStockMember 2024-06-30 0001706431 us-gaap:AdditionalPaidInCapitalMember 2024-06-30 0001706431 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-06-30 0001706431 us-gaap:RetainedEarningsMember 2024-06-30 0001706431 us-gaap:NoncontrollingInterestMember 2024-06-30 0001706431 2024-06-30 0001706431 us-gaap:CommonStockMember 2024-07-01 2024-09-30 0001706431 us-gaap:AdditionalPaidInCapitalMember 2024-07-01 2024-09-30 0001706431 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-07-01 2024-09-30 0001706431 us-gaap:RetainedEarningsMember 2024-07-01 2024-09-30 0001706431 us-gaap:CommonStockMember 2024-09-30 0001706431 us-gaap:AdditionalPaidInCapitalMember 2024-09-30 0001706431 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-09-30 0001706431 us-gaap:RetainedEarningsMember 2024-09-30 0001706431 us-gaap:NoncontrollingInterestMember 2024-09-30 0001706431 us-gaap:CommonStockMember 2023-06-30 0001706431 us-gaap:AdditionalPaidInCapitalMember 2023-06-30 0001706431 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-06-30 0001706431 us-gaap:RetainedEarningsMember 2023-06-30 0001706431 us-gaap:NoncontrollingInterestMember 2023-06-30 0001706431 2023-06-30 0001706431 us-gaap:CommonStockMember 2023-07-01 2023-09-30 0001706431 us-gaap:AdditionalPaidInCapitalMember 2023-07-01 2023-09-30 0001706431 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-07-01 2023-09-30 0001706431 us-gaap:RetainedEarningsMember 2023-07-01 2023-09-30 0001706431 us-gaap:CommonStockMember 2023-09-30 0001706431 us-gaap:AdditionalPaidInCapitalMember 2023-09-30 0001706431 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-09-30 0001706431 us-gaap:RetainedEarningsMember 2023-09-30 0001706431 us-gaap:NoncontrollingInterestMember 2023-09-30 0001706431 2023-09-30 0001706431 us-gaap:CommonStockMember 2023-12-31 0001706431